Tactical Therapeutics on WSJ
Special Biotechnology Report 24 June 2009, Washington Post. Click here to download the pdf
BIOWIRE 2K, 9 May 2006 , Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006
CTO has multiple molecular targets :
Inhibit Ca++ signaling (anti-proliferative, antimetaastatic apoptotic)
Inhibits P13 kinase, No2, VEGF (tumorcell migration and adhesion),
CoX2 IL-1 inhibitor
